We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene Corp. (CNC - Free Report) is a well diversified, multi-national healthcare company that has been provides a set of services to the government sponsored healthcare programs since 1954.
The Wisconsin-based company has grown substantially in the last three years through acquisitions, partnerships and alliances. The company’s operating performance has been improving consistently over last few years. Financial liquidity has supported the company’s inorganic growth initiatives that have been the main revenue driver till date. Continuous focus on maximizing shareholders value has always made the stock lucrative to investors.
However, Centene suffers from rising level of debts. Consistently surging expenses also remain a major threat for the company. Moreover, Donald Trump’s decision to repeal former President Barrack Obama's Affordable Care Act (ACA), that has casted an air of uncertainty on the medical sector, also remains a major headwind for this company.
Centene has a decent history when it comes to earnings as the company has beaten estimates in three of the last four quarters, making for an average surprise of 7%.
Managed care membership of 12.1 million, rose 5% over 2016.
Health benefits ratio (HBR) was 87.6% in the first quarter of 2017, compared to 88.7% in the prior year quarter.
Total Operating Expenses of $11.5 billion increased 64.3% over the prior year quarter.
Operating cash flow was $1.25 million in the first quarter of 2017, compared to only $196 million in the last year quarter.
For 2017, Centene expects adjusted earnings per diluted share to be in the range of $4.50- $4.90. Total revenues are expected to be in the range of $46 billion to $46.8 billion.
Check back later for our full write up on this Centene earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Centene's (CNC) Q1 Earnings, Revenues Beat Estimates
Centene Corp. (CNC - Free Report) is a well diversified, multi-national healthcare company that has been provides a set of services to the government sponsored healthcare programs since 1954.
The Wisconsin-based company has grown substantially in the last three years through acquisitions, partnerships and alliances. The company’s operating performance has been improving consistently over last few years. Financial liquidity has supported the company’s inorganic growth initiatives that have been the main revenue driver till date. Continuous focus on maximizing shareholders value has always made the stock lucrative to investors.
However, Centene suffers from rising level of debts. Consistently surging expenses also remain a major threat for the company. Moreover, Donald Trump’s decision to repeal former President Barrack Obama's Affordable Care Act (ACA), that has casted an air of uncertainty on the medical sector, also remains a major headwind for this company.
Centene has a decent history when it comes to earnings as the company has beaten estimates in three of the last four quarters, making for an average surprise of 7%.
Currently, Centene holds a Zacks Rank #3 (Hold), but that could definitely change following its earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Centene beats on earnings. Our consensus called for EPS of $1.06, and the company reported adjusted diluted EPS of $1.12.
Revenue: Operating revenues beat our estimate. Our consensus called for revenues of $11.4 billion, and the company reported revenues of $11.7 billion.
Centene Corporation Price and EPS Surprise
Centene Corporation Price and EPS Surprise | Centene Corporation Quote
Key Stats to Note:
Managed care membership of 12.1 million, rose 5% over 2016.
Health benefits ratio (HBR) was 87.6% in the first quarter of 2017, compared to 88.7% in the prior year quarter.
Total Operating Expenses of $11.5 billion increased 64.3% over the prior year quarter.
Operating cash flow was $1.25 million in the first quarter of 2017, compared to only $196 million in the last year quarter.
For 2017, Centene expects adjusted earnings per diluted share to be in the range of $4.50- $4.90. Total revenues are expected to be in the range of $46 billion to $46.8 billion.
Check back later for our full write up on this Centene earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging
phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>